BostonGene to Showcase Novel Genomic Classifier and Immunotherapy Selection Framework at SOHO 2026
Data highlight translational NGS approaches to refine patient stratification, guide target selection, and accelerate precision drug development in hematologic malignancies
BostonGene, developer of the leading AI model for tumor and immune biology, today announced that two abstracts have been accepted for poster presentation at Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9 - 12 in Houston, Texas. The 14th Annual Meeting will bring together thousands of global experts to showcase practice-changing breakthroughs and practical clinical applications in blood cancer treatment.
At SOHO 2026, BostonGene will highlight advanced molecular stratification frameworks designed to unlock actionable insights from complex multimodal datasets. These studies provide biopharma partners with robust translational tools to optimize patient selection, guide treatment sequencing, and accelerate precision oncology pipelines across B-cell lymphomas and multiple myeloma.
Details about the abstracts selected for presentation can be found below:
